Barriers to CAR T-Cell Therapy for LBCL Challenge Physicians and Patients

Key opinion leaders discuss barriers to care for using CAR T-cell therapy for patients with large B-cell lymphoma, including time delays and lack of support for patients.

Related Keywords

Minnesota ,United States ,Washington ,Stanford ,California ,Vermont ,Mayo Clinic In Rochester ,Tufts Medical Center ,Massachusetts ,Boston ,Seattle ,Dana Farber Cancer Institute ,Ankur Mehta ,Caron Jacobson ,Robertr Koch ,Paul Unger ,Wen Kai Weng ,Amir Modarressi ,Ajayk Gopal ,Stanford Health Care ,Harvard Medical School ,Foundation For The Accreditation Of Cellular Therapy ,Us Lymphoma Cart Consortium ,Kite Pharma Inc ,Cellular Therapy Network ,Bristolmyers Squibb ,United States Lymphoma Cart Consortium ,Fred Hutch Cancer Center ,Effector Cell Therapy Program ,Bellevue Medical Center ,Cellular Therapy ,Case Based Roundtable ,Immune Effector Cell Therapy Program ,Harvard Medical ,Kai Weng ,Sarah Cannon Transplant ,Vizient Clinical ,Champlain Valley Hematology Oncology ,United States Lymphoma ,Mayo Clinic ,Accessed July ,Tandem Meetings ,Cellular Therapy Meetings ,Myers Squibb ,Contributing Kite ,Diffuse Largeb Cell Lymphoma ,Cart Cell Therapy ,